Profile - To The Moon

KennethLim

Posts · 357Posts · 357
Following · 0Following · 0
Followers · 0Followers · 0

- KennethLimKennethLim
  ·01-17
  $Frencken(E28.SI)$
  335 Comment
  1
  Share
  Report
- KennethLimKennethLim
  ·2023-12-13
  $Frencken(E28.SI)$
  425 Comment
  Like
  Share
  Report
- KennethLimKennethLim
  ·2023-01-07
  Ha!
  China in Talks With Pfizer for Generic COVID Drug
  HONG KONG/BEIJING, Jan 6 (Reuters) - China is in talks with Pfizer Inc to secure a licence that will
  China in Talks With Pfizer for Generic COVID Drug
  281 Comment
  Like
  Share
  Report
- KennethLimKennethLim
  ·2023-01-07
  K
  Dethroned "SPAC King" Thinks Musk Will Take Starlink Public This Year
  Chamath Palihapitiya made the prediction on his podcast All-InSpaceX CEO previously said Starlink IP
  Dethroned "SPAC King" Thinks Musk Will Take Starlink Public This Year
  599 1
  3
  Share
  Report
- KennethLimKennethLim
  ·2022-11-22
  Ok
  3 Stocks to Avoid This Week
  These investments seem pretty vulnerable right now.
  3 Stocks to Avoid This Week
  716 3
  8
  Share
  Report
- KennethLimKennethLim
  ·2022-10-25
  k
  [REWARDS] How has your stock performed this year?
  @TigerEvents：
  Hi Tigers:I would like to invite you to share your positions and to win Tiger Coins.Sharing positions is simple. From your account holdings interface, you can click "Share" by each of your stock holdings to discuss with the community how much money you have made (or lost) on your investments.Due to the Fed's recent increase in interest rates, many stocks have fallen, particularly the technology sector, which has entered the "discounting season" early this year. The share prices of$Alphabet(GOOG)$ and$Amazon.com(AMZN)$ have fallen more than 30% so far this year. The share prices of $Tesla Motors(TSLA)$ have fallen more than 40% so far this year.
  [REWARDS] How has your stock performed this year?
  356 Comment
  Like
  Share
  Report
- KennethLimKennethLim
  ·2022-09-28
  Thanks
  329 Comment
  Like
  Share
  Report
- KennethLimKennethLim
  ·2022-09-15
  $OVERSEA-CHINESE BANKING CORP(O39.SI)$i like ocbc with his stable income & dividend. Price is stable and not volatile. Good to keep for long term.
  727 9
  8
  Share
  Report
- KennethLimKennethLim
  ·2022-09-14
  $NIO Inc.(NIO.SI)$good run for Nio, from 18 to 21 & heading to 22
  405 Comment
  2
  Share
  Report
- KennethLimKennethLim
  ·2022-09-13
  $Apple(AAPL)$i didn't monitorvfor months & the price goes up for 10%!
  505 Comment
  Like
  Share
  Report

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":"3573516985440152","uuid":"3573516985440152","gmtCreate":1610430742833,"gmtModify":1662610003668,"name":"KennethLim","pinyin":"kennethlim","introduction":"","introductionEn":"","signature":"","avatar":"https://community-static.tradeup.com/news/b14c36aded4c09af72784800119db550","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":12,"headSize":27,"tweetSize":357,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":4,"name":"文化虎","nameTw":"文化虎","represent":"学有所成","factor":"发布30条非转发主帖,其中3条优质帖","iconColor":"8867FB","bgColor":"BDC5FF"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":1,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.10.10","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"44212b71d0be4ec88898348dbe882e03-2","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Executive Tiger","description":"The transaction amount of the securities account reaches $300,000","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"80.72%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.02.12","exceedPercentage":"60.84%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":{"badgeId":"44212b71d0be4ec88898348dbe882e03-1","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Boss Tiger","description":"The transaction amount of the securities account reaches $100,000","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.22","exceedPercentage":"60.28%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},"individualDisplayBadges":null,"crmLevel":5,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":7,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":263853833371928,"gmtCreate":1705453103928,"gmtModify":1705453106955,"author":{"id":"3573516985440152","authorId":"3573516985440152","name":"KennethLim","avatar":"https://community-static.tradeup.com/news/b14c36aded4c09af72784800119db550","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573516985440152","idStr":"3573516985440152"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/E28.SI\">$Frencken(E28.SI)$ </a>&nbsp;","listText":"<a href=\"https://ttm.financial/S/E28.SI\">$Frencken(E28.SI)$ </a>&nbsp;","text":"$Frencken(E28.SI)$","images":[{"img":"https://community-static.tradeup.com/news/96efe3c78fd28659b4688e50d9328648","width":"870","height":"1708"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/263853833371928","isVote":1,"tweetType":1,"viewCount":335,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":251461901549624,"gmtCreate":1702429277621,"gmtModify":1702429280415,"author":{"id":"3573516985440152","authorId":"3573516985440152","name":"KennethLim","avatar":"https://community-static.tradeup.com/news/b14c36aded4c09af72784800119db550","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573516985440152","idStr":"3573516985440152"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/E28.SI\">$Frencken(E28.SI)$ </a>&nbsp;","listText":"<a href=\"https://ttm.financial/S/E28.SI\">$Frencken(E28.SI)$ </a>&nbsp;","text":"$Frencken(E28.SI)$","images":[{"img":"https://community-static.tradeup.com/news/b1ca05d8e617f01acd009bfbe5ab85d4","width":"870","height":"1708"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/251461901549624","isVote":1,"tweetType":1,"viewCount":425,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9959735123,"gmtCreate":1673065107762,"gmtModify":1676538783116,"author":{"id":"3573516985440152","authorId":"3573516985440152","name":"KennethLim","avatar":"https://community-static.tradeup.com/news/b14c36aded4c09af72784800119db550","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573516985440152","idStr":"3573516985440152"},"themes":[],"htmlText":"Ha!","listText":"Ha!","text":"Ha!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9959735123","repostId":"2301748452","repostType":4,"repost":{"id":"2301748452","kind":"news","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1673046905,"share":"https://ttm.financial/m/news/2301748452?lang=&edition=fundamental","pubTime":"2023-01-07 07:15","market":"us","language":"en","title":"China in Talks With Pfizer for Generic COVID Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2301748452","media":"Reuters","summary":"HONG KONG/BEIJING, Jan 6 (Reuters) - China is in talks with Pfizer Inc to secure a licence that will","content":"<html><head></head><body><p>HONG KONG/BEIJING, Jan 6 (Reuters) - China is in talks with Pfizer Inc to secure a licence that will allow domestic drugmakers to manufacture and distribute a generic version of the U.S. firm&#39;s COVID-19 antiviral drug Paxlovid in China, three sources told Reuters.</p><p>China&#39;s medical products regulator - the National Medical Products Administration (NMPA) - has been leading the talks with Pfizer since late last month, one of the sources with knowledge of the matter said.</p><p>Beijing is keen to finalise licensing deal terms before the Lunar New Year which begins on Jan. 22, the source said.</p><p>Chinese hospitals are under intense pressure after the government abruptly abandoned its &#34;zero-COVID&#34; policy last month, sending infections soaring. The surging wave of infections across the country has overwhelmed hospitals, emptied pharmacies of medicines and caused international alarm.</p><p>Paxlovid, found to have reduced hospitalisations in high-risk patients by around 90% in a clinical trial, is in high demand with many Chinese attempting to get the drug abroad and have it shipped to China. Beijing has been largely resistant to western vaccines and treatments. Oral treatment Paxlovid is one of the few foreign ones it has approved.</p><p>In February last year, China approved Paxlovid, which was supposed to be largely available via hospitals, to treat high-risk patients in several provinces. Pfizer last month reached an agreement to export Paxlovid to China through a local company to make the medicine more widely available.</p><p>The NMPA and the State Council Information Office, which handles media queries for the government, did not respond to Reuters requests for comment.</p><p>A Pfizer spokesperson said the company is actively collaborating with Chinese authorities and all stakeholders to secure an adequate supply of Paxlovid in China.</p><p>All the sources declined to be identified as they are not authorised to speak to media.</p><p>The NMPA held a meeting with several Chinese drugmakers in late December to discuss preparations needed to make a generic version of Paxlovid hoping it would be able to secure the licence in the near future, two of the sources said.</p><p>Zhejiang Huahai Pharmaceutical, which signed a deal with Pfizer in August to produce Paxlovid only for use on the mainland, and CSPC Pharmaceutical Group, a developer of a potential mRNA COVID vaccine, are among those that attended the meeting, the first source said.</p><p>The second source said the NMPA has also advised firms to prepare to register with the regulator to produce the generic version of Paxlovid.</p><h2>GENERIC DRUGMAKERS</h2><p>Prospective candidates including Huahai and CSPC have in recent weeks been conducting &#34;bioequivalence tests&#34;, which are required by Chinese regulators before generic drugs can be launched, the two sources and another source with direct knowledge of the matter said.</p><p>For a generic drug to be deemed equivalent to a branded medicine, such tests are required to make sure they work the same way in the body.</p><p>Both Huahai and CSPC expect to submit the tests results to the NMPA later this month, one of them added.</p><p>Huahai and CSPC did not respond to a request for comment.</p><p>In March, 35 generic drugmakers around the world including five Chinese firms agreed to make cheap versions of Paxlovid for 95 poorer countries through a licensing arrangement with the U.N.-backed Medicines Patent Pool (MPP). That licence does not allow the companies to sell generic Paxlovid in China.</p><p>The MPP licensing arrangement is royalty free for Pfizer, while COVID-19 remains classified as a &#34;Public Health Emergency of International Concern&#34; by the World Health Organization (WHO).</p><p>Following the pandemic period, sales to low-income countries will remain royalty free, lower-middle-income countries and upper-middle-income countries will be subject to a 5% royalty for sales to the public sector and a 10% royalty for sales to the private sector, MPP said at that time.</p><p>Due to severe shortages of antivirals as 1.4 billion Chinese battle infections, many have turned to underground channels to secure Paxlovid and other drugs, according to domestic media. Scalpers charge as much as 50,000 yuan ($7,260) for a box of Paxlovid, more than 20 times its original price of 2,300 yuan.</p><p>China has also pressed Pfizer to lower the price of Paxlovid as the government aims to include the drug in the national medical insurance scheme which could cover part of the cost, the three sources said.</p><p>($1 = 6.8875 Chinese yuan)</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China in Talks With Pfizer for Generic COVID Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina in Talks With Pfizer for Generic COVID Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2023-01-07 07:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>HONG KONG/BEIJING, Jan 6 (Reuters) - China is in talks with Pfizer Inc to secure a licence that will allow domestic drugmakers to manufacture and distribute a generic version of the U.S. firm&#39;s COVID-19 antiviral drug Paxlovid in China, three sources told Reuters.</p><p>China&#39;s medical products regulator - the National Medical Products Administration (NMPA) - has been leading the talks with Pfizer since late last month, one of the sources with knowledge of the matter said.</p><p>Beijing is keen to finalise licensing deal terms before the Lunar New Year which begins on Jan. 22, the source said.</p><p>Chinese hospitals are under intense pressure after the government abruptly abandoned its &#34;zero-COVID&#34; policy last month, sending infections soaring. The surging wave of infections across the country has overwhelmed hospitals, emptied pharmacies of medicines and caused international alarm.</p><p>Paxlovid, found to have reduced hospitalisations in high-risk patients by around 90% in a clinical trial, is in high demand with many Chinese attempting to get the drug abroad and have it shipped to China. Beijing has been largely resistant to western vaccines and treatments. Oral treatment Paxlovid is one of the few foreign ones it has approved.</p><p>In February last year, China approved Paxlovid, which was supposed to be largely available via hospitals, to treat high-risk patients in several provinces. Pfizer last month reached an agreement to export Paxlovid to China through a local company to make the medicine more widely available.</p><p>The NMPA and the State Council Information Office, which handles media queries for the government, did not respond to Reuters requests for comment.</p><p>A Pfizer spokesperson said the company is actively collaborating with Chinese authorities and all stakeholders to secure an adequate supply of Paxlovid in China.</p><p>All the sources declined to be identified as they are not authorised to speak to media.</p><p>The NMPA held a meeting with several Chinese drugmakers in late December to discuss preparations needed to make a generic version of Paxlovid hoping it would be able to secure the licence in the near future, two of the sources said.</p><p>Zhejiang Huahai Pharmaceutical, which signed a deal with Pfizer in August to produce Paxlovid only for use on the mainland, and CSPC Pharmaceutical Group, a developer of a potential mRNA COVID vaccine, are among those that attended the meeting, the first source said.</p><p>The second source said the NMPA has also advised firms to prepare to register with the regulator to produce the generic version of Paxlovid.</p><h2>GENERIC DRUGMAKERS</h2><p>Prospective candidates including Huahai and CSPC have in recent weeks been conducting &#34;bioequivalence tests&#34;, which are required by Chinese regulators before generic drugs can be launched, the two sources and another source with direct knowledge of the matter said.</p><p>For a generic drug to be deemed equivalent to a branded medicine, such tests are required to make sure they work the same way in the body.</p><p>Both Huahai and CSPC expect to submit the tests results to the NMPA later this month, one of them added.</p><p>Huahai and CSPC did not respond to a request for comment.</p><p>In March, 35 generic drugmakers around the world including five Chinese firms agreed to make cheap versions of Paxlovid for 95 poorer countries through a licensing arrangement with the U.N.-backed Medicines Patent Pool (MPP). That licence does not allow the companies to sell generic Paxlovid in China.</p><p>The MPP licensing arrangement is royalty free for Pfizer, while COVID-19 remains classified as a &#34;Public Health Emergency of International Concern&#34; by the World Health Organization (WHO).</p><p>Following the pandemic period, sales to low-income countries will remain royalty free, lower-middle-income countries and upper-middle-income countries will be subject to a 5% royalty for sales to the public sector and a 10% royalty for sales to the private sector, MPP said at that time.</p><p>Due to severe shortages of antivirals as 1.4 billion Chinese battle infections, many have turned to underground channels to secure Paxlovid and other drugs, according to domestic media. Scalpers charge as much as 50,000 yuan ($7,260) for a box of Paxlovid, more than 20 times its original price of 2,300 yuan.</p><p>China has also pressed Pfizer to lower the price of Paxlovid as the government aims to include the drug in the national medical insurance scheme which could cover part of the cost, the three sources said.</p><p>($1 = 6.8875 Chinese yuan)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0122379950.USD":"贝莱德世界健康科学A2","PFE":"辉瑞","BK4581":"高盛持仓","SG9999001176.USD":"United Global Healthcare Acc USD","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","BK4124":"机动车零配件与设备","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","BK4585":"ETF&股票定投概念","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","BK4534":"瑞士信贷持仓","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","SG9999002232.USD":"Allianz Global High Payout USD","LU0234572021.USD":"高盛美国核心股票组合Acc","BK4007":"制药","SG9999002224.SGD":"Allianz Global High Payout SGD","LU0058720904.USD":"联博国际健康护理基金A","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2301748452","content_text":"HONG KONG/BEIJING, Jan 6 (Reuters) - China is in talks with Pfizer Inc to secure a licence that will allow domestic drugmakers to manufacture and distribute a generic version of the U.S. firm's COVID-19 antiviral drug Paxlovid in China, three sources told Reuters.China's medical products regulator - the National Medical Products Administration (NMPA) - has been leading the talks with Pfizer since late last month, one of the sources with knowledge of the matter said.Beijing is keen to finalise licensing deal terms before the Lunar New Year which begins on Jan. 22, the source said.Chinese hospitals are under intense pressure after the government abruptly abandoned its \"zero-COVID\" policy last month, sending infections soaring. The surging wave of infections across the country has overwhelmed hospitals, emptied pharmacies of medicines and caused international alarm.Paxlovid, found to have reduced hospitalisations in high-risk patients by around 90% in a clinical trial, is in high demand with many Chinese attempting to get the drug abroad and have it shipped to China. Beijing has been largely resistant to western vaccines and treatments. Oral treatment Paxlovid is one of the few foreign ones it has approved.In February last year, China approved Paxlovid, which was supposed to be largely available via hospitals, to treat high-risk patients in several provinces. Pfizer last month reached an agreement to export Paxlovid to China through a local company to make the medicine more widely available.The NMPA and the State Council Information Office, which handles media queries for the government, did not respond to Reuters requests for comment.A Pfizer spokesperson said the company is actively collaborating with Chinese authorities and all stakeholders to secure an adequate supply of Paxlovid in China.All the sources declined to be identified as they are not authorised to speak to media.The NMPA held a meeting with several Chinese drugmakers in late December to discuss preparations needed to make a generic version of Paxlovid hoping it would be able to secure the licence in the near future, two of the sources said.Zhejiang Huahai Pharmaceutical, which signed a deal with Pfizer in August to produce Paxlovid only for use on the mainland, and CSPC Pharmaceutical Group, a developer of a potential mRNA COVID vaccine, are among those that attended the meeting, the first source said.The second source said the NMPA has also advised firms to prepare to register with the regulator to produce the generic version of Paxlovid.GENERIC DRUGMAKERSProspective candidates including Huahai and CSPC have in recent weeks been conducting \"bioequivalence tests\", which are required by Chinese regulators before generic drugs can be launched, the two sources and another source with direct knowledge of the matter said.For a generic drug to be deemed equivalent to a branded medicine, such tests are required to make sure they work the same way in the body.Both Huahai and CSPC expect to submit the tests results to the NMPA later this month, one of them added.Huahai and CSPC did not respond to a request for comment.In March, 35 generic drugmakers around the world including five Chinese firms agreed to make cheap versions of Paxlovid for 95 poorer countries through a licensing arrangement with the U.N.-backed Medicines Patent Pool (MPP). That licence does not allow the companies to sell generic Paxlovid in China.The MPP licensing arrangement is royalty free for Pfizer, while COVID-19 remains classified as a \"Public Health Emergency of International Concern\" by the World Health Organization (WHO).Following the pandemic period, sales to low-income countries will remain royalty free, lower-middle-income countries and upper-middle-income countries will be subject to a 5% royalty for sales to the public sector and a 10% royalty for sales to the private sector, MPP said at that time.Due to severe shortages of antivirals as 1.4 billion Chinese battle infections, many have turned to underground channels to secure Paxlovid and other drugs, according to domestic media. Scalpers charge as much as 50,000 yuan ($7,260) for a box of Paxlovid, more than 20 times its original price of 2,300 yuan.China has also pressed Pfizer to lower the price of Paxlovid as the government aims to include the drug in the national medical insurance scheme which could cover part of the cost, the three sources said.($1 = 6.8875 Chinese yuan)","news_type":1},"isVote":1,"tweetType":1,"viewCount":281,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9959735976,"gmtCreate":1673065098195,"gmtModify":1676538783109,"author":{"id":"3573516985440152","authorId":"3573516985440152","name":"KennethLim","avatar":"https://community-static.tradeup.com/news/b14c36aded4c09af72784800119db550","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573516985440152","idStr":"3573516985440152"},"themes":[],"htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9959735976","repostId":"1199658349","repostType":4,"repost":{"id":"1199658349","kind":"news","pubTimestamp":1673059317,"share":"https://ttm.financial/m/news/1199658349?lang=&edition=fundamental","pubTime":"2023-01-07 10:41","market":"us","language":"en","title":"Dethroned \"SPAC King\" Thinks Musk Will Take Starlink Public This Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1199658349","media":"Bloomberg","summary":"Chamath Palihapitiya made the prediction on his podcast All-InSpaceX CEO previously said Starlink IP","content":"<html><head></head><body><ul><li>Chamath Palihapitiya made the prediction on his podcast All-In</li><li>SpaceX CEO previously said Starlink IPO was four years away</li></ul><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/8742a2aad739ea9b2aecec68b7469791\" tg-width=\"1000\" tg-height=\"667\" width=\"100%\" height=\"auto\"/><span>Chamath Palihapitiya Photographer: David Paul Morris/Bloomberg</span></p><p>Chamath Palihapitiya, a former Facebook Inc. executive and prominent investor known for his “blank-check” companies, is predicting that SpaceX’s internet-from-space initiative Starlink will go public in 2023, years earlier than planned.</p><p>Palihapitiya said on his podcast <i>All-In</i> that a Starlink IPO could give chief executive Elon Musk more financial flexibility and would be “an obvious outcome in 2023.”</p><p>The comments came on the episode of the podcast where he and his two co-hosts, investors Jason Calacanis and David Sacks, predict trends and events across the technology industry in the year ahead.</p><p>“[Musk] talked about this on our pod, about the difficulties and the dangers of margin loans and all of that stuff,” Palihapitiya said. “He’s going to create breathing room for himself. This is the simplest and most obvious way for him to do it. It’ll give him a ton of more dry powder.”</p><p>It wasn’t clear from his comments whether he had information about specific plans from Space Exploration Technologies Corp. or was just speculating. While Palihapitiya is not known to be particularly close to Musk, both co-hosts Calacanis and Sacks are, and have been involved in the SpaceX and Tesla Inc. CEO’s recent ownership of Twitter Inc.</p><p>Both Musk and SpaceX’s president, Gwynne Shotwell, have made various comments over the years about the Starlink initiative eventually breaking off from the rest of the company and going public. In February 2020, after SpaceX had launched a couple hundred Starlink satellites, Shotwell said that the unit was “the right kind of business that we can go ahead and take public.” However, shortly after her comments, Musk said that SpaceX was thinking “zero” about a Starlink IPO.</p><p>“We need to make the thing work,” he said during a fireside chat in Washington.</p><p>Musk said in spring 2022 during a SpaceX all-hands meeting that a Starlink IPO was at least three to four years away, CNBC reported.</p><p>A public offering this year might not be the best timing. Concerns about a slowing economy limited IPOs in 2022, and rising interest rates and a potential US recession continue to be drags on the market.</p><p>Palihapitiya has spent the past three years taking startups public through special-purpose acquisition companies, blank-check firms that provide an alternate route to IPOs or direct listings. His promotion of these investments and so-called meme stocks led to him being unofficially crowned the “SPAC King.</p><p>Like other SPAC companies and the tech market at large, many of Palihapitiya’s investments have lost significant value since he took them public. Online bank SoFi Technologies Inc. has fallen 79% since June 2021. Space tourism company Virgin Galactic Holdings Inc. has dropped 66%. Two of his blank-check companies shuttered in September after failing to find deals.</p><p>Palihapitiya and SpaceX did not immediately respond to requests for comment.</p><p>SpaceX’s Starlink program entails launching thousands of satellites into low orbits above Earth in order to provide global low-latency broadband internet service to the ground below. So far, the company has more than 3,300 satellites in orbit, and SpaceX recently claimed to have 1 million subscribers. In December, SpaceX also received authorization from the US Federal Communications Commission to launch an additional 7,500 satellites, part of a new shell called Gen 2.</p></body></html>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dethroned \"SPAC King\" Thinks Musk Will Take Starlink Public This Year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDethroned \"SPAC King\" Thinks Musk Will Take Starlink Public This Year\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-01-07 10:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2023-01-06/dethroned-spac-king-chamath-palihapitiya-thinks-musk-will-ipo-starlink-this-year?srnd=technology-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Chamath Palihapitiya made the prediction on his podcast All-InSpaceX CEO previously said Starlink IPO was four years awayChamath Palihapitiya Photographer: David Paul Morris/BloombergChamath ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2023-01-06/dethroned-spac-king-chamath-palihapitiya-thinks-musk-will-ipo-starlink-this-year?srnd=technology-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"source_url":"https://www.bloomberg.com/news/articles/2023-01-06/dethroned-spac-king-chamath-palihapitiya-thinks-musk-will-ipo-starlink-this-year?srnd=technology-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199658349","content_text":"Chamath Palihapitiya made the prediction on his podcast All-InSpaceX CEO previously said Starlink IPO was four years awayChamath Palihapitiya Photographer: David Paul Morris/BloombergChamath Palihapitiya, a former Facebook Inc. executive and prominent investor known for his “blank-check” companies, is predicting that SpaceX’s internet-from-space initiative Starlink will go public in 2023, years earlier than planned.Palihapitiya said on his podcast All-In that a Starlink IPO could give chief executive Elon Musk more financial flexibility and would be “an obvious outcome in 2023.”The comments came on the episode of the podcast where he and his two co-hosts, investors Jason Calacanis and David Sacks, predict trends and events across the technology industry in the year ahead.“[Musk] talked about this on our pod, about the difficulties and the dangers of margin loans and all of that stuff,” Palihapitiya said. “He’s going to create breathing room for himself. This is the simplest and most obvious way for him to do it. It’ll give him a ton of more dry powder.”It wasn’t clear from his comments whether he had information about specific plans from Space Exploration Technologies Corp. or was just speculating. While Palihapitiya is not known to be particularly close to Musk, both co-hosts Calacanis and Sacks are, and have been involved in the SpaceX and Tesla Inc. CEO’s recent ownership of Twitter Inc.Both Musk and SpaceX’s president, Gwynne Shotwell, have made various comments over the years about the Starlink initiative eventually breaking off from the rest of the company and going public. In February 2020, after SpaceX had launched a couple hundred Starlink satellites, Shotwell said that the unit was “the right kind of business that we can go ahead and take public.” However, shortly after her comments, Musk said that SpaceX was thinking “zero” about a Starlink IPO.“We need to make the thing work,” he said during a fireside chat in Washington.Musk said in spring 2022 during a SpaceX all-hands meeting that a Starlink IPO was at least three to four years away, CNBC reported.A public offering this year might not be the best timing. Concerns about a slowing economy limited IPOs in 2022, and rising interest rates and a potential US recession continue to be drags on the market.Palihapitiya has spent the past three years taking startups public through special-purpose acquisition companies, blank-check firms that provide an alternate route to IPOs or direct listings. His promotion of these investments and so-called meme stocks led to him being unofficially crowned the “SPAC King.Like other SPAC companies and the tech market at large, many of Palihapitiya’s investments have lost significant value since he took them public. Online bank SoFi Technologies Inc. has fallen 79% since June 2021. Space tourism company Virgin Galactic Holdings Inc. has dropped 66%. Two of his blank-check companies shuttered in September after failing to find deals.Palihapitiya and SpaceX did not immediately respond to requests for comment.SpaceX’s Starlink program entails launching thousands of satellites into low orbits above Earth in order to provide global low-latency broadband internet service to the ground below. So far, the company has more than 3,300 satellites in orbit, and SpaceX recently claimed to have 1 million subscribers. In December, SpaceX also received authorization from the US Federal Communications Commission to launch an additional 7,500 satellites, part of a new shell called Gen 2.","news_type":1},"isVote":1,"tweetType":1,"viewCount":599,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9968020335,"gmtCreate":1669079289627,"gmtModify":1676538148147,"author":{"id":"3573516985440152","authorId":"3573516985440152","name":"KennethLim","avatar":"https://community-static.tradeup.com/news/b14c36aded4c09af72784800119db550","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573516985440152","idStr":"3573516985440152"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/9968020335","repostId":"2285904055","repostType":4,"repost":{"id":"2285904055","kind":"highlight","pubTimestamp":1669089004,"share":"https://ttm.financial/m/news/2285904055?lang=&edition=fundamental","pubTime":"2022-11-22 11:50","market":"us","language":"en","title":"3 Stocks to Avoid This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2285904055","media":"Motley Fool","summary":"These investments seem pretty vulnerable right now.","content":"<html><head></head><body><p>Last week was a letdown for investors long the market after a strong rally the week before. The &#34;three stocks to avoid&#34; in my column that I thought were going to lose to the market last week -- <b>Coinbase</b>, <b>Despegar.com</b>, and <b><a href=\"https://laohu8.com/S/BOWL\">Bowlero</a></b> -- fell 21%, 12%, and 12%, respectively, averaging out to a 15% plunge.</p><p>The <b>S&amp;P 500</b> experienced only a 0.7% move lower. I was right. I have been correct in 36 of the past 57 weeks, or 63% of the time.</p><p>Now let&#39;s look at the week ahead. I see <b>Best Buy</b>, <b>Luckin Coffee</b>, and <b>Apple</b> as stocks you might want to consider steering clear of this week. Let&#39;s go over my near-term concerns with all three investments.</p><h2><b>1. Best Buy</b></h2><p>Best Buy&#39;s revival a few years ago was a thing of beauty. Now we&#39;re seeing that the last major consumer-electronics superstore chain still standing is on wobbly legs.</p><p>The retailer reports fresh financials on Tuesday morning, and it won&#39;t be pretty. Analysts see revenue clocking in 13% lower than the prior-year&#39;s fiscal third quarter. Its profit is expected to be cut in half.</p><p>The near-term outlook is uninspiring. Wall Street pros see revenue slipping 11% for the current holiday quarter, as well as the entire fiscal 2023 year that ends in January. Profitability should take a bigger hit. If you&#39;re buying Best Buy for that chunky 4.9% yield, that&#39;s a dicey proposition when its bottom line is going the wrong way.</p><p>Rising costs and the inability of a brick-and-mortar chain to compete on price with bare-boned online merchants are making life hard for Best Buy, again. Now we have a potentially dimming economy setting back demand for consumer electronics.</p><p>To be fair, Best Buy&#39;s renaissance wasn&#39;t that exciting. You have to go back to fiscal 2009 -- 14 years -- to find the last time that this chain delivered top-line gains in the double digits.</p><h2><b>2. Luckin Coffee</b></h2><p>If you were to construct the perfect stock to avoid in a lab, it would probably look a lot like Luckin Coffee. It&#39;s a China-based company at a time when most investors outside of the country are steering clear of the market.</p><p>Let&#39;s also not forget that Luckin Coffee is a stock that -- like its hot java -- already burned investors before. You surely remember the accounting scandal of 2020.</p><p>Have you checked on Luckin Coffee stock lately? The stock is a 20-bagger off its C-suite drama low. The shares ended this past week within 0.5% of a new two-year high, nearly quadrupling from this-year&#39;s springtime bottom. We&#39;ll get an update on how it&#39;s brewing when it pours a cup of third-quarter results on Tuesday.</p><p>Luckin Coffee has done a commendable job turning things around. After years of losses, it was profitable in 2021. Revenue continued to grow.</p><p>However, Luckin Coffee&#39;s top-line gains have decelerated for four consecutive quarters. It also posted a loss in its previous quarter. It&#39;s hard to get excited about Luckin Coffee. It may seem like a low-priced indulgence, but it&#39;s a luxury that consumers will avoid if they need to save their money for more-pressing expenses.</p><h2><b>3. Apple</b></h2><p>Let&#39;s wrap-up this-week&#39;s list by picking on the country&#39;s most valuable company by market cap. I&#39;m a longtime fan and investor in Apple, but I can see why it&#39;s a scary stock to hold heading into this particular holiday shopping season. The economy is on iffy footing, credit card debit is rising, and Apple isn&#39;t going to be immune from consumers steering clear of big-ticket purchases this season.</p><p>Apple held up well when most tech stocks got slammed earlier this year, but the class act of Cupertino is finally proving mortal. It doesn&#39;t help that its annual refresh of popular products wasn&#39;t overly impressive. With money already tight, it&#39;s easy to see consumers ride this year out and see what Apple springs on us in 2023.</p><p>Analysts aren&#39;t excited. They see revenue and earnings per share rising a mere 3% and 2%, respectively, for the new fiscal year.</p><p>It&#39;s going to be a bumpy road for some of these investments. If you&#39;re looking for safe stocks, you aren&#39;t likely to find them in Best Buy, Luckin Coffee, and Apple this week.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Stocks to Avoid This Week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Stocks to Avoid This Week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-11-22 11:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/11/21/3-stocks-to-avoid-this-week/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Last week was a letdown for investors long the market after a strong rally the week before. The \"three stocks to avoid\" in my column that I thought were going to lose to the market last week -- ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/11/21/3-stocks-to-avoid-this-week/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LKNCY":"瑞幸咖啡","AAPL":"苹果","BBY":"百思买"},"source_url":"https://www.fool.com/investing/2022/11/21/3-stocks-to-avoid-this-week/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2285904055","content_text":"Last week was a letdown for investors long the market after a strong rally the week before. The \"three stocks to avoid\" in my column that I thought were going to lose to the market last week -- Coinbase, Despegar.com, and Bowlero -- fell 21%, 12%, and 12%, respectively, averaging out to a 15% plunge.The S&P 500 experienced only a 0.7% move lower. I was right. I have been correct in 36 of the past 57 weeks, or 63% of the time.Now let's look at the week ahead. I see Best Buy, Luckin Coffee, and Apple as stocks you might want to consider steering clear of this week. Let's go over my near-term concerns with all three investments.1. Best BuyBest Buy's revival a few years ago was a thing of beauty. Now we're seeing that the last major consumer-electronics superstore chain still standing is on wobbly legs.The retailer reports fresh financials on Tuesday morning, and it won't be pretty. Analysts see revenue clocking in 13% lower than the prior-year's fiscal third quarter. Its profit is expected to be cut in half.The near-term outlook is uninspiring. Wall Street pros see revenue slipping 11% for the current holiday quarter, as well as the entire fiscal 2023 year that ends in January. Profitability should take a bigger hit. If you're buying Best Buy for that chunky 4.9% yield, that's a dicey proposition when its bottom line is going the wrong way.Rising costs and the inability of a brick-and-mortar chain to compete on price with bare-boned online merchants are making life hard for Best Buy, again. Now we have a potentially dimming economy setting back demand for consumer electronics.To be fair, Best Buy's renaissance wasn't that exciting. You have to go back to fiscal 2009 -- 14 years -- to find the last time that this chain delivered top-line gains in the double digits.2. Luckin CoffeeIf you were to construct the perfect stock to avoid in a lab, it would probably look a lot like Luckin Coffee. It's a China-based company at a time when most investors outside of the country are steering clear of the market.Let's also not forget that Luckin Coffee is a stock that -- like its hot java -- already burned investors before. You surely remember the accounting scandal of 2020.Have you checked on Luckin Coffee stock lately? The stock is a 20-bagger off its C-suite drama low. The shares ended this past week within 0.5% of a new two-year high, nearly quadrupling from this-year's springtime bottom. We'll get an update on how it's brewing when it pours a cup of third-quarter results on Tuesday.Luckin Coffee has done a commendable job turning things around. After years of losses, it was profitable in 2021. Revenue continued to grow.However, Luckin Coffee's top-line gains have decelerated for four consecutive quarters. It also posted a loss in its previous quarter. It's hard to get excited about Luckin Coffee. It may seem like a low-priced indulgence, but it's a luxury that consumers will avoid if they need to save their money for more-pressing expenses.3. AppleLet's wrap-up this-week's list by picking on the country's most valuable company by market cap. I'm a longtime fan and investor in Apple, but I can see why it's a scary stock to hold heading into this particular holiday shopping season. The economy is on iffy footing, credit card debit is rising, and Apple isn't going to be immune from consumers steering clear of big-ticket purchases this season.Apple held up well when most tech stocks got slammed earlier this year, but the class act of Cupertino is finally proving mortal. It doesn't help that its annual refresh of popular products wasn't overly impressive. With money already tight, it's easy to see consumers ride this year out and see what Apple springs on us in 2023.Analysts aren't excited. They see revenue and earnings per share rising a mere 3% and 2%, respectively, for the new fiscal year.It's going to be a bumpy road for some of these investments. If you're looking for safe stocks, you aren't likely to find them in Best Buy, Luckin Coffee, and Apple this week.","news_type":1},"isVote":1,"tweetType":1,"viewCount":716,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9988141116,"gmtCreate":1666705240836,"gmtModify":1676537793002,"author":{"id":"3573516985440152","authorId":"3573516985440152","name":"KennethLim","avatar":"https://community-static.tradeup.com/news/b14c36aded4c09af72784800119db550","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573516985440152","idStr":"3573516985440152"},"themes":[],"htmlText":"k","listText":"k","text":"k","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9988141116","repostId":"9988149248","repostType":1,"repost":{"id":9988149248,"gmtCreate":1666704929585,"gmtModify":1676537792709,"author":{"id":"3527667667103859","authorId":"3527667667103859","name":"TigerEvents","avatar":"https://community-static.tradeup.com/news/c266ef25181ace18bec1262357bbe1a8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3527667667103859","idStr":"3527667667103859"},"themes":[],"title":"[REWARDS] How has your stock performed this year?","htmlText":"Hi Tigers:I would like to invite you to share your positions and to win Tiger Coins.Sharing positions is simple. From your account holdings interface, you can click \"Share\" by each of your stock holdings to discuss with the community how much money you have made (or lost) on your investments.Due to the Fed's recent increase in interest rates, many stocks have fallen, particularly the technology sector, which has entered the \"discounting season\" early this year.&nbsp;The share prices of<a href=\"https://ttm.financial/S/GOOG\">$Alphabet(GOOG)$</a> and<a href=\"https://ttm.financial/S/AMZN\">$Amazon.com(AMZN)$</a> have fallen more than 30% so far this year. The share prices of <a href=\"https://ttm.financial/S/TSLA\">$Tesla Motors(TSLA)$</a> have fallen more than 40% so far this year.","listText":"Hi Tigers:I would like to invite you to share your positions and to win Tiger Coins.Sharing positions is simple. From your account holdings interface, you can click \"Share\" by each of your stock holdings to discuss with the community how much money you have made (or lost) on your investments.Due to the Fed's recent increase in interest rates, many stocks have fallen, particularly the technology sector, which has entered the \"discounting season\" early this year.&nbsp;The share prices of<a href=\"https://ttm.financial/S/GOOG\">$Alphabet(GOOG)$</a> and<a href=\"https://ttm.financial/S/AMZN\">$Amazon.com(AMZN)$</a> have fallen more than 30% so far this year. The share prices of <a href=\"https://ttm.financial/S/TSLA\">$Tesla Motors(TSLA)$</a> have fallen more than 40% so far this year.","text":"Hi Tigers:I would like to invite you to share your positions and to win Tiger Coins.Sharing positions is simple. From your account holdings interface, you can click \"Share\" by each of your stock holdings to discuss with the community how much money you have made (or lost) on your investments.Due to the Fed's recent increase in interest rates, many stocks have fallen, particularly the technology sector, which has entered the \"discounting season\" early this year. The share prices of$Alphabet(GOOG)$ and$Amazon.com(AMZN)$ have fallen more than 30% so far this year. The share prices of $Tesla Motors(TSLA)$ have fallen more than 40% so far this year.","images":[{"img":"https://static.tigerbbs.com/b403c20c141980924fa878bf76a65edc","width":"-1","height":"-1"}],"top":1,"highlighted":1,"essential":2,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9988149248","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"subType":2,"comments":[],"imageCount":2,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":356,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9918343175,"gmtCreate":1664327123597,"gmtModify":1676537433232,"author":{"id":"3573516985440152","authorId":"3573516985440152","name":"KennethLim","avatar":"https://community-static.tradeup.com/news/b14c36aded4c09af72784800119db550","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573516985440152","idStr":"3573516985440152"},"themes":[],"htmlText":"Thanks","listText":"Thanks","text":"Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9918343175","isVote":1,"tweetType":1,"viewCount":329,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9934117776,"gmtCreate":1663204159795,"gmtModify":1676537226395,"author":{"id":"3573516985440152","authorId":"3573516985440152","name":"KennethLim","avatar":"https://community-static.tradeup.com/news/b14c36aded4c09af72784800119db550","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573516985440152","idStr":"3573516985440152"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/O39.SI\">$OVERSEA-CHINESE BANKING CORP(O39.SI)$</a>i like ocbc with his stable income &amp; dividend. Price is stable and not volatile. Good to keep for long term.","listText":"<a href=\"https://ttm.financial/S/O39.SI\">$OVERSEA-CHINESE BANKING CORP(O39.SI)$</a>i like ocbc with his stable income &amp; dividend. Price is stable and not volatile. Good to keep for long term.","text":"$OVERSEA-CHINESE BANKING CORP(O39.SI)$i like ocbc with his stable income & dividend. Price is stable and not volatile. Good to keep for long term.","images":[{"img":"https://community-static.tradeup.com/news/f1c5139ba2b781ed3ce599b8d286dcf5","width":"1080","height":"2672"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":9,"repostSize":0,"link":"https://ttm.financial/post/9934117776","isVote":1,"tweetType":1,"viewCount":727,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9935435409,"gmtCreate":1663120190001,"gmtModify":1676537208095,"author":{"id":"3573516985440152","authorId":"3573516985440152","name":"KennethLim","avatar":"https://community-static.tradeup.com/news/b14c36aded4c09af72784800119db550","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573516985440152","idStr":"3573516985440152"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/NIO.SI\">$NIO Inc.(NIO.SI)$</a>good run for Nio, from 18 to 21 &amp; heading to 22","listText":"<a href=\"https://ttm.financial/S/NIO.SI\">$NIO Inc.(NIO.SI)$</a>good run for Nio, from 18 to 21 &amp; heading to 22","text":"$NIO Inc.(NIO.SI)$good run for Nio, from 18 to 21 & heading to 22","images":[{"img":"https://community-static.tradeup.com/news/1c3153a4810cf824c1e36ec6afcbe29a","width":"1080","height":"2672"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9935435409","isVote":1,"tweetType":1,"viewCount":405,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":9935951126,"gmtCreate":1663028492866,"gmtModify":1676537184953,"author":{"id":"3573516985440152","authorId":"3573516985440152","name":"KennethLim","avatar":"https://community-static.tradeup.com/news/b14c36aded4c09af72784800119db550","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573516985440152","idStr":"3573516985440152"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/AAPL\">$Apple(AAPL)$</a>i didn't monitorvfor months &amp; the price goes up for 10%!","listText":"<a href=\"https://ttm.financial/S/AAPL\">$Apple(AAPL)$</a>i didn't monitorvfor months &amp; the price goes up for 10%!","text":"$Apple(AAPL)$i didn't monitorvfor months & the price goes up for 10%!","images":[{"img":"https://community-static.tradeup.com/news/70a6ba79b86bc1ff0af5b5dbc24ed4a4","width":"1080","height":"2233"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9935951126","isVote":1,"tweetType":1,"viewCount":505,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":true}